Below is shown the sector allocation of the fund - the biggest part is around 26.9% in the "Consumer Discretionary". ACP has ...

Liquidia Corporation remains a Buy for risk-tolerant biotech investors, supported by strong Yutrepia launch metrics and ...

Exclusive, Inc. surges on Starlink Aviation dealer news, but revenue impact is modest and upside priced in. Click for this ...

Roundhill WeeklyPay Universe ETF has solid core holdings and the fund's strategy is simple but should be effective. Learn ...

CMPS has benefited from positive phase 3 trial results and positive political developments since my last article. Click here ...

Glencore plc is a top commodity trader/producer poised to benefit from rising base metals and macro tailwinds—click to see ...

Kratos Defense & Security Solutions, Inc. outlook: drone-driven defense growth forecasts 14–23% through 2027, but risks ...

As a trader, operating without the Commitments of Traders (COT) report during the recent 43-day govt. shutdown felt like ...

Novo Nordisk is my top opportunity for 2026, driven by multiple catalysts and a compelling valuation. The Wegovy pill's FDA ...

Tiptree trades at a 27% discount to pro forma book value after the Fortegra sale, amid tax and governance concerns. Read the ...

Aoje Inc. is pursuing a $30 million US IPO to fund growth amid deteriorating financials and declining revenue. Read the full ...

Renaissance IPO ETF (IPO) is rated a buy, anticipating a surge in major IPOs through 2026 to fuel renewed investor interest.